… , breakthrough CMV infection while receiving prophylaxis … on LD prophylaxis developed
breakthrough CMV infection with an … 1 patient developing GCV-resistant infection. In 28 patients …

… generally receive 90 days of valganciclovir prophylaxis after transplantation with the …
breakthrough during administration of prophylaxis. This event was defined as CMV infection …

… Here we report a fast breakthrough of resistant cytomegalovirus during secondary LMV
prophylaxis in … Ganciclovir (GCV) and valganciclovir (valGCV) are routinely used for treating CMV …

… at least 3 months of valganciclovir prophylaxis was planned. … , as well as other
infections in the first year posttransplant and … year after prophylaxis or during prophylaxis (breakthrough) …

… Clinically relevant CMV infection, CMV infection, and CMV breakthrough infection were …
After that we performed a multivariable analysis with CMV breakthrough infection as time-…

… valganciclovir to letermovir from November 2017 to June 2020. The primary outcome was the
rate of CMV breakthrough infections while on prophylaxis. … valganciclovir, the breakthrough …

… breakthrough infections have been reported for a small subgroup of recipients across various
transplant settings worldwide, despite the use of valganciclovir prophylaxis (… Valganciclovir …

… , which is a greater frequency of surveillance than that reported in recent publications and
could account for the higher observed rate of breakthrough infections in this study.11, 12 …

… has lowered the incidence of CMV infection and its … , breakthrough infections during
valganciclovir prophylaxis and late CMV infection after cessation of valganciclovir prophylaxis still …

… Patients with breakthrough CMV reactivation ≥200 IU/mL … breakthrough CMV infection
during letermovir prophylaxis. … treated preemptively with ganciclovir, valganciclovir, or foscarnet …